Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial? - PubMed (original) (raw)

. 2016 Dec;39(12):e212-e213.

doi: 10.2337/dc16-1312. Epub 2016 Sep 27.

Affiliations

• PMID: 27679584
• DOI: 10.2337/dc16-1312

Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?

Subodh Verma et al. Diabetes Care. 2016 Dec.

No abstract available

PubMed Disclaimer

Similar articles

• Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics.
  Scheen AJ. Scheen AJ. Diabetes Metab. 2016 Sep;42(4):224-33. doi: 10.1016/j.diabet.2016.05.006. Epub 2016 Jun 10. Diabetes Metab. 2016. PMID: 27291329 Review.
• Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.
  Scheen AJ, Delanaye P. Scheen AJ, et al. Diabetes Metab. 2017 Apr;43(2):99-109. doi: 10.1016/j.diabet.2016.12.010. Epub 2017 Jan 30. Diabetes Metab. 2017. PMID: 28153377 Review.
• Impact of EMPA-REG OUTCOME® on the management of type 2 diabetes mellitus: a review for primary care physicians.
  Naing S, Poliyedath A, Khandelwal S, Sigala T. Naing S, et al. Postgrad Med. 2016 Nov;128(8):822-827. doi: 10.1080/00325481.2016.1245093. Epub 2016 Oct 25. Postgrad Med. 2016. PMID: 27701934 Review.
• Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial.
  Verma S, Mazer CD, Bhatt DL, Raj SR, Yan AT, Verma A, Ferrannini E, Simons G, Lee J, Zinman B, George JT, Fitchett D. Verma S, et al. Diabetes Care. 2019 Mar;42(3):e42-e44. doi: 10.2337/dc18-1959. Epub 2019 Jan 23. Diabetes Care. 2019. PMID: 30674547 No abstract available.
• EMPA-REG OUTCOME: The Cardiologist's Point of View.
  Pham SV, Chilton R. Pham SV, et al. Am J Med. 2017 Jun;130(6S):S57-S62. doi: 10.1016/j.amjmed.2017.04.006. Am J Med. 2017. PMID: 28526181

Cited by

• The Comparison of the Effectiveness of Dapagliflozin and Empagliflozin in the Prevention of Cardiovascular Outcomes in Patients With Type 2 Diabetes: A Network Meta-Analysis.
  Sinha T, Gul U, Babar NN, Israr F, Butt AA, Chaudhari SS, Maqbool H, Amin A. Sinha T, et al. Cureus. 2024 Sep 19;16(9):e69711. doi: 10.7759/cureus.69711. eCollection 2024 Sep. Cureus. 2024. PMID: 39429324 Free PMC article. Review.
• Efficacy of Sodium-Glucose 2 Transporter Inhibitors in Heart Failure With Preserved Ejection Fraction: A Narrative Review.
  Maged R, Sinha M, Koneru HM, Sarwar H, Bandi VV, Tarar P, Halawa N. Maged R, et al. Cureus. 2024 Sep 17;16(9):e69623. doi: 10.7759/cureus.69623. eCollection 2024 Sep. Cureus. 2024. PMID: 39429273 Free PMC article. Review.
• New insights into the cardio-renal benefits of SGLT2 inhibitors and the coordinated role of miR-30 family.
  El Khayari A, Hakam SM, Malka G, Rochette L, El Fatimy R. El Khayari A, et al. Genes Dis. 2023 Nov 23;11(6):101174. doi: 10.1016/j.gendis.2023.101174. eCollection 2024 Nov. Genes Dis. 2023. PMID: 39224109 Free PMC article. Review.
• Effects of SGLT2 Inhibitors on Cardiac Mechanics in Hispanic and Black Diabetic Patients.
  Moras E, Shrivastav R, Gandhi KD, Bandyopadhyay D, Isath A, Goel A, Bella JN, Contreras J. Moras E, et al. J Clin Med. 2024 Aug 4;13(15):4555. doi: 10.3390/jcm13154555. J Clin Med. 2024. PMID: 39124821 Free PMC article.
• Impact of sodium-glucose cotransporter-2 inhibitor use on peak VO2 in advanced heart failure patients.
  Desai A, Sharma S, Abuah N, Jang J, Desai S, Paghdhar S, Goswami RM. Desai A, et al. Front Cardiovasc Med. 2024 Jul 24;11:1376645. doi: 10.3389/fcvm.2024.1376645. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39114558 Free PMC article.

Publication types

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Other Literature Sources

  • scite Smart Citations